ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
EudraCT number 2012-004034-42
Protocol number GS-US-313-0125
Sponsor Gilead Sciences, Inc.,333 Lakeside Drive, Foster City, California 94404, United States
Indications Oncology
Diagnosis Indolent Non-Hodgkin Lymphomas
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2013
Date of approval by Institute (SÚKL) 28.8.2013
Date of approval by EC 27.6.2013
Date of initiation CT in ČR 2.12.2013
Date of ending CT in ČR 11.3.2016 (7.3.2016)
Notice
Sites Fakultní nemocnice Brno,,Jihlavská 20,Brno,625 00
Fakultní nemocnice Hradec Králové,,Sokolská 581,Hradec Králové,500 05
Fakultní nemocnice Ostrava ,,17. listopadu 1790,Ostrava,708 52

‹‹ Back to list